Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug shows promise for treating kidney cancer

30.10.2007
The new drug axitinib has shown promising activity in patients with cytokine-refractory, metastatic kidney cancer that traditionally have a poor response to drug treatment, according to an Article in the November issue of The Lancet Oncology.

In the USA, kidney cancer is the sixth leading cause of cancer deaths, and is thought to be responsible for nearly 13 000 deaths a year. Kidney cancer is not a single disease, but is made up of several different types of cancer, each of which has different histological features, has a different clinical course, and responds differently to treatment.

The most common type is clear-cell renal cancer, which accounts for 75% of patients. Treatment options are limited and survival is poor, and responses with use of chemotherapy, hormonal, or biological treatment, and even with some of the new targeted drugs, seldom exceed 10%.

Professor Olivier Rixe (University of Paris, France) and colleagues report findings from a phase II trial of axitinib-a selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3-in 52 patients with cytokine-refractory, metastatic kidney cancer (51 of whom had clear-cell renal cancer). 23 patients had complete or partial responses, some of which were long-lasting: 12 of these patients progressed during the study, with a duration of response ranging from around 4 months to 26 months. Additionally, 22 patients showed stable disease for longer than 8 weeks, including 13 patients with stable disease for 24 weeks or longer. Four patients had early disease progression. 30 patients had hypertension related to the treatment, but side-effects in general were manageable and controlled by dose modification or supportive care.

Selectively targeting a single growth factor receptor pathway could provide the potential to rationally adjust dosages and combine drugs directed at specific parts of the pathway to minimise toxicity and achieve the optimum therapeutic benefit. Professor Rixe concludes that “The objective response and time to progression in our study suggest that axitinib might be a promising drug in the treatment of patients with metastatic renal-cell cancer; although a randomised controlled trial is needed to confirm this finding.”

In an accompanying Reflection and Reaction comment, Dr W Marston Linehan (National Cancer Institute, Bethesda, MA, USA) states that these findings “suggest that a drug such as axitinib has promise as a second-line treatment in cytokine-refractory metastatic renal-cell carcinoma, and might have potential as first-line treatment or in combination with other agents targeting the Von Hippel-Lindau pathway (or both).”

Tony Kirby | alfa
Further information:
http://www.thelancet.com

More articles from Health and Medicine:

nachricht Collagen nanofibrils in mammalian tissues get stronger with exercise
14.12.2018 | University of Illinois College of Engineering

nachricht New discoveries predict ability to forecast dementia from single molecule
12.12.2018 | UT Southwestern Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Data use draining your battery? Tiny device to speed up memory while also saving power

The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.

Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...

Im Focus: An energy-efficient way to stay warm: Sew high-tech heating patches to your clothes

Personal patches could reduce energy waste in buildings, Rutgers-led study says

What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...

Im Focus: Lethal combination: Drug cocktail turns off the juice to cancer cells

A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.

The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...

Im Focus: New Foldable Drone Flies through Narrow Holes in Rescue Missions

A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.

Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...

Im Focus: Topological material switched off and on for the first time

Key advance for future topological transistors

Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

EGU 2019 meeting: Media registration now open

06.12.2018 | Event News

 
Latest News

Data use draining your battery? Tiny device to speed up memory while also saving power

14.12.2018 | Power and Electrical Engineering

Tangled magnetic fields power cosmic particle accelerators

14.12.2018 | Physics and Astronomy

In search of missing worlds, Hubble finds a fast evaporating exoplanet

14.12.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>